Insulin independence for LCT
Tuesday, 07 April, 2009
New Zealand’s Living Cell Technologies has reported that a patient with type 1 diabetes is currently insulin independent following treatments in an early stage trial.
LCT is running the safety and dosing trial in Moscow. Seven patients have received Diabecell implants at a low or medium dose.
Diabecell is a microencapsulated product containing insulin-producing porcine islet cells. In the female patient, live porcine cells in their capsules have been found in the abdomen and porcine insulin was detected in her blood.
The 37-year-old had been on daily insulin injections for 15 years. She is now maintaining good blood glucose control without injections, LCT said.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
